Novo Nordisk

NVO

Market cap $259B

Overview Fund Activity

58.20 USD

+1.00

1.75%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

62.22

+4.02

6.91%

1 day

1.75%

5 days

8.54%

1 month

8.28%

3 months

-21.71%

6 months

-27.39%

Year to date

-33.5%

1 year

-55.91%

5 years

67.29%

10 years

105.29%

About: With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 78,387

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1% more repeat investments, than reductions

Existing positions increased: 569 | Existing positions reduced: 562

0% more funds holding in top 10

Funds holding in top 10: 24 [Q1] → 24 (+0) [Q2]

0.47% less ownership

Funds ownership: 9.54% [Q1] → 9.07% (-0.47%) [Q2]

3% less funds holding

Funds holding: 1,508 [Q1] → 1,460 (-48) [Q2]

7% less capital invested

Capital invested by funds: $22.9B [Q1] → $21.2B (-$1.69B) [Q2]

12% less first-time investments, than exits

New positions opened: 138 | Existing positions closed: 157

30% less call options, than puts

Call options by funds: $1.14B | Put options by funds: $1.63B

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$70

20% upside

Avg. target

$70

20% upside

High target

$70

20% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

TD Cowen

Michael Nedelcovych

$70

Buy

Maintained

19 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 223 articles about NVO published over the past 30 days

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Bagsværd, Denmark, 18 September 2025 – Novo Nordisk today announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, Ozempic® (once-weekly injectable semaglutide) was associated with a reduced risk of major adverse cardiovascular events such as a heart attack or stroke by 23%1. The data span nearly 60,000 US Medicare patients (aged ≥66 years) living with type 2 diabetes, atherosclerotic cardiovascular disease (ASCVD) – a condition where fatty deposits build up in blood vessels, reducing blood flow and increasing the risk of heart attacks, strokes and related problems – and multiple health conditions2. The results were presented at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting on 15–19 September in Vienna, Austria1.

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Novo Nordisk's Wegovy Pill Shows Similar Weight-Loss to Its Shot, Study Finds

Production is under way and the pill, which helped patients lose an average 16.6% of their weight, is pending regulatory approval in the U.S.

Novo Nordisk's Wegovy Pill Shows Similar Weight-Loss to Its Shot, Study Finds

Wegovy pill offers 'significant' weight reduction, Novo Nordisk says, as oral obesity drug race intensifies

Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said. The company's Chief Science Officer Martin Holst Lange told CNBC that oral treatment offered an important alternative to its existing injection for patients.

Wegovy pill offers 'significant' weight reduction, Novo Nordisk says, as oral obesity drug race intensifies

NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

NEW YORK , Sept. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the "Class Period"), of the important September 30, 2025 lead plaintiff deadline.

NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

CNBC Television

Market delayed in reaction to Novo Nordisk and Eli Lilly' s GLP-1 pills, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk competition in the GLP-1 pill space between Novo Nordisk and Eli Lilly.

Market delayed in reaction to Novo Nordisk and Eli Lilly' s GLP-1 pills, says Mizuho's Jared Holz

Novo Nordisk A/S - Special Call

Novo Nordisk A/S - Special Call Company Participants Martin Lange - EVP of R&D, CSO and Member of the Management Board Conference Call Participants Martin Parkhoi - SEB, Research Division Michael Novod - Nordea Markets, Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Mattias Häggblom - Handelsbanken Capital Markets AB, Research Division Conor MacKay - BMO Capital Markets Equity Research Presentation Operator Okay.

Novo Nordisk A/S - Special Call

Novo Nordisk says Wegovy pill shows comparable weight-loss to injectable version

Novo Nordisk's experimental Wegovy pill showed a 16.6% weight-loss in a late-stage study, according to data published in The New England Journal of Medicine on Wednesday, which is comparable to previous trial results of injectable Wegovy.

Novo Nordisk says Wegovy pill shows comparable weight-loss to injectable version

Novo Nordisk's oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

Bagsværd, Denmark, Plainsboro, NJ, 17 September 2025 – Today, The New England Journal of Medicine published the results from the OASIS 4 phase 3 trial that studied the efficacy and safety of the investigational once-daily oral semaglutide 25 mg (Wegovy ® in a pill*), marking a significant milestone in the company's ambition to advance obesity care. In the 64-week trial, oral semaglutide 25 mg, alongside lifestyle modifications, was compared to placebo in 307 adults with obesity or overweight with one or more weight-related comorbidities, without diabetes.1

Novo Nordisk's oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

NVO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVO

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”), of the important September 30, 2025 lead plaintiff deadline.

NVO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVO

Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa , Sept. 17, 2025 /PRNewswire/ -- The Law Offices of Howard G.

Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

See News Rankings

Charts implemented using Lightweight Charts™